After continuous drug flops in pivotal clinical trials for AD, a new hope has risen since the recent discovery of PrPC as a high-affinity binding partner of amyloid β (Aβ) oligomers, which are the key pathophysiological toxic entities causing neuronal death in AD patients [169]. This evidence concerns the gene PRNP and Alzheimer disease.